CAR-T 细胞治疗后的 B 细胞缺乏:发生率、动力学、预后意义与临床管理 B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management. PubMed 2026/08/19 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T急性淋巴细胞白血病慢性淋巴细胞白血病大B细胞淋巴瘤
CAR-T 细胞治疗后的免疫效应细胞相关噬血细胞性淋巴组织细胞增生症:一项真实世界研究结果 Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study. PubMed 2026/05/14 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤套细胞淋巴瘤多发性骨髓瘤地区:欧洲
工程化抗 BCMA CAR-T 细胞通过凋亡调控增强骨髓瘤杀伤效力 Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation. PubMed 2025/05/19 发表Nat CommunQ1 · IF 18.1(JCR 2025) 靶点:BCMA技术:CAR-T多发性骨髓瘤套细胞淋巴瘤地区:欧洲
CAR-T 细胞与过继性 T 细胞疗法在淋巴及实体器官恶性肿瘤中的综述 A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies. PubMed 2025/02/02 发表Med Sci MonitQ3 · IF 2.5(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:TIL急性淋巴细胞白血病慢性淋巴细胞白血病大B细胞淋巴瘤
靶向三种受体和多种 B 细胞肿瘤的 BAFF 配体 CAR-T 细胞 A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. PubMed 2022/01/11 发表Nat CommunQ1 · IF 18.1(JCR 2025) 靶点:BCMA技术:CAR-T急性淋巴细胞白血病套细胞淋巴瘤多发性骨髓瘤地区:美国